{
  "ticker": "BOD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971510",
  "id": "02971510",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250722",
  "time": "1554",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m0zglgsy3b3z.pdf",
  "summary": "### **Appendix 4C Quarterly Report Summary (Bod Science Limited)**  \n\n#### **Key Financial Highlights:**  \n- **Net cash from operating activities (Qtr):** $858k  \n- **Closing cash balance:** $1.037M (includes $400k held in trust for Biortica if acquisition completes).  \n- **Government grants/R&D tax incentive received:** $678k (offset by $51k owed to ATO).  \n- **Proceeds from intellectual property sale:** $125k (part of $176k total transaction).  \n\n#### **Capital Structure & Liquidity:**  \n- **No outstanding debt facilities** (total drawn/available: $0).  \n- **Biortica partially funded trading costs** (disclosed under \"other inflows\").  \n- **Positive operating cash flow** (no funding shortfall; no capital raising steps disclosed).  \n\n#### **Material Notes:**  \n- **Deed of Company Arrangement** status disclosed (potential acquisition by Biortica pending).  \n- **$461k bank overdraft** partially offsets reported cash balance.  \n\n**Brevity Note:** Excluded routine line-item details (e.g., staff costs, R&D) as no material deviations or surprises. Focus on liquidity position and contingent items.",
  "usage": {
    "prompt_tokens": 2820,
    "completion_tokens": 260,
    "total_tokens": 3080,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T05:58:31.864301"
}